The development of vancomycin resistance in a patient with methicillin- resistant Staphylococcus aureus infection

New England Journal of Medicine

Volumn 340, Issue 7, 1999, Pages 517-523

  Sieradzki, Krzysztof ^a   Roberts, Richard B ^a,b   Haber, Stuart W ^c   Tomasz, Alexander ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c United Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; TOBRAMYCIN; VANCOMYCIN;

AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM IDENTIFICATION; BLOOD CULTURE; CASE REPORT; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; STRAIN DIFFERENCE;

AGED; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; ELECTROPHORESIS, GEL, PULSED-FIELD; FATAL OUTCOME; HUMANS; KIDNEY FAILURE, CHRONIC; LACTAMS; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; NEW YORK CITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0033580211     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199902183400704     Document Type: Article

References (12)

1. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-3.
2. Staphylococcus aureus with reduced susceptibility to vancomycin -United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:765-6. [Erratum, MMWR Morb Mortal Wkly Rep 1997;46:851.]
3. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:813-5. [Erratum, MMWR Morb Mortal Wkly Rep 1997;46:851.]
4. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998;36:1020-7. [Erratum, J Clin Microbiol 1998;36:2167.]
5. Roberts RB, de Lencastre A, Eisner W, et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus in 12 New York hospitals. J Infect Dis 1998;178:164-71.
6. de Lencastre H, Severina EP, Roberts RB, Kreiswirth BN, Tomasz A, BARG Initiative Pilot Study Group. Testing the efficacy of a molecular surveillance network: methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF) genotypes in six hospitals in the metropolitan New York City area. Microb Drug Resist 1996;2: 343-51.
7. de Lencastre H, Tomasz A. Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1994;38:2590-8.
8. Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 1998;42:100-7.
9. Tomasz A, Jamieson JD, Ottolenghi E. The fine structure of Diplococcus pneumoniae. J Cell Biol 1964;22:453-67.
10. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997;179:2557-66.
11. Idem. Suppression of β-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. J Antimicrob Chemother 1997;39: Suppl A:47-51.
12. Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-8.